After eight years at the helm of Eli Lilly, a tenure characterized by a steadfast belief in home-grown research, rather than deals, John Lechleiter is retiring from the Indianapolis pharma giant.
Lilly (NYSE: LLY) said this morning that Lechleiter, its... Read more »
South San Francisco, CA-based drug developer Cytokinetics stumbled two years ago, but a deal with Astellas Pharma could be a big step toward recovery.
Astellas, of Tokyo, is paying Cytokinetics (NASDAQ: CYTK) $65 million for an option to the rights... Read more »
Ostendo Technologies, a Carlsbad, CA-based company founded in 2005 to advance curved screens and other innovative display technologies, has raised $41.8 million of a new financing round intended to bring in $62.8 million, according to a recent regulatory filing.
The financing... Read more »
LogMeIn plans to join forces with a division of rival Citrix Systems in a $1.8 billion deal aimed at creating a juggernaut in the world of cloud-based business software.
For much of its 13-year history, Boston-based LogMeIn (NASDAQ: LOGM) has... Read more »
Kadmon Holdings tempered its expectations and managed to go public late Wednesday, despite its founders’ criminal history and a heavy debt load.
New York-based Kadmon raised $75 million by selling 6.25 million shares at $12 each. But to get there, it... Read more »
Austin—Dropoff founder and CEO Sean Spector makes it a point to emphasize that the Austin, TX-based startup is a delivery service for businesses.
“We are an extension of these businesses and their brands,” he says. “We deliver valuable medication, sensitive... Read more »
[Updated 7/26/16, 5:15 pm. See below.] Shares in Exact Sciences were up more than 28 percent on Tuesday after the company released second quarter financial results that handily beat analyst expectations.
Madison, WI-based Exact (NASDAQ: EXAS), whose flagship product is... Read more »
With the Republican National Convention behind us and the Democratic convention in full swing, it seems like a good moment to ask how a Donald Trump presidency or a Hillary Clinton presidency might affect the prospects for high-tech entrepreneurship and business... Read more »
Tokai Pharmaceuticals has been trying to play catch-up for years in the fast-moving field of prostate cancer treatments. But that plan just took a major hit this morning.
Cambridge, MA-based Tokai (NASDAQ: TKAI) said that an independent data monitoring committee... Read more »